Methacrylated-κ-carrageenan/hydroxyapatite composite bioinks for extrusion-based bioprinting: Physicochemical, rheological, mechanical, and in vitro biological investigations.
Kansız S., Vurat MT., Parmaksiz M., Elçin AE., Elçin YM.
Laboratory Study, published in Int J Biol Macromol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Int J Biol Macromol (2025)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40447004
- DOI
- 10.1016/j.ijbiomac.2025.144745
Abstract (original English)
Composite hydrogels are of interest in modulating the rheological properties of bioinks for extrusion-based 3D-bioprinting. In this study, new composite bioinks composed of different levels of methacrylated κ-carrageenan (κ-Car-L-MA, κ-Car-M-MA, and κ-Car-H-MA) and hydroxyapatite (HAp) were prepared and evaluated for extrusion-based 3D-bioprinting applications, focusing on printability, mechanical and physicochemical properties. The methacrylation degree and incorporation of HAp were found to significantly affect the printing performance of bioinks. Semi-quantitative printability assessment revealed that κ-Car-M-MA and κ-Car-M-MA-HAp bioinks exhibited optimal printability. The mechanical behavior of the bioinks appeared to depend on the methacrylation degree, which affects compressive modulus and toughness. Bioprinting studies were conducted to create a bilayer model using human adipose-derived stem cells and an almost two-fold increase in cell viability in the printed constructs was observed on the seventh day of culture. The findings suggest that the developed bioink composition demonstrates significant potential for 3D-bioprinting-based biomedical applications.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.